Alzheimer’s Disease: An Epidemiologic Disaster From Nutritional Perspective

Magda Antal1, Szabolcs Péter2*, Manfred Eggersdorfer2,3

1Pannónia Street 66, Budapest 1133, Hungary
2DSM Nutritional Products Ltd., Wurmisweg 576, Kaiseraugst 4303, Switzerland
3University Medical Center Groningen, University of Groningen, Hanzeplein 1, The Netherlands

Received: November 20, 2016; Accepted: December 15, 2016; Published: January 25, 2017
*Corresponding author: Szabolcs Péter MD, PhD, Principal Scientist, DSM Nutritional Products Ltd., P.O. Box 2676, 4002 Basel, Switzerland, Tel.: +41 61 815 8966; Fax: +41 61 815 8540; E-mail: szabolcs.peter@dsm.com

Abstract

Alzheimer disease (AD) is a progressive, multifactorial, untreatable neurodegenerative disease with worldwide increasing incidence and prevalence in the ageing societies. Besides pharmaceutical drug development there is also a need for alternative solutions for both prevention and treatment. The major objective of this article is to summarize the non-modifiable and some modifiable risk factors of AD, including nutrition and diet, and to discuss different aspects of AD prevention. Optimizing the nutritional status of the general population as a preventive measure may provide additional support to therapeutic concepts as they become available. Already several randomized controlled trials demonstrated promising results for certain nutrients to decrease the risk of developing AD and maintaining cognitive performance. Moreover, symptoms of AD such as neuroinflammation, glucose dysregulation, homocysteine accumulation and neuronal loss can be considerably influenced by nutrition. Thus, lifelong optimal supply of essential micro- and macronutrients may contribute to delay the onset of AD. However, currently the scientific evidence regarding the effects of nutrients on AD is incomplete and there are many opportunities for nutrition scientists to contribute to the clarification of the conflicting results and adjust guidelines accordingly.

Keywords: Alzheimer’s Disease; Public Health; Nutrition; Vitamins; Polyunsaturated Fatty Acids.

Introduction

In 2015, globally the average Life Expectancy (LE) at birth was 71.4 years, while the healthy life expectancy at birth was 63.1 years [1]. However, there are great differences in LE among countries and between genders: For example in the US men live 76.9 years on average, while women live 81.6 years; these data in the UK are 79.4 and 83.0 years, respectively; while Japan has one of the highest LE in the world for men (80.5 years) and for women (86.8 years) as well [2].

The share of population aged 65 and over is increasing in every EU member state: In 2014 the 65-79 years age group represented 13.4% of the population, while the rate of people aged 80 years and over was 5.1%. The estimated ratio of these two age groups in the 28 EU countries for 2040 is 17.9% and 9.9%, and for 2050 it is projected to be 17.2% and 10.9%, respectively [3] (Figure 1).

Based on the data available, LE during the 20th century increased by more than 30 years. By the year 2040 more than a quarter of the Europeans will be older than 65 years and one in seven will be at least 75 years of age. More importantly, health expectancy on average is 8-11 years shorter than LE and loss of cognitive functions and increase in dementia are major contributors of disability and disease during these last couple years of life [4, 5].

Alzheimer’s Disease (AD) is the most common cause of dementia in people aged 60 years or older, representing approximately 60-70% of all cases [6].

Currently at least 35 million people are affected by AD worldwide and this number is expected to quadruple by the year 2050. Although mortality due to HIV, stroke and heart disease decreased between 2000 and 2013 by 52%, 23% and 14%, respectively, death cases related to AD increased by 71% within the same timeframe, making AD the fourth leading cause of death in developed countries [7].

The prevalence of AD increases with age, for example the proportion of people with AD in the US in 2015 was estimated as follows: <65 years: 4%; 65-74 years: 15%; 75-84 years: 43%; 85+ years: 38% [7].

Definition of AD

Alois Alzheimer identified the first case of AD in a 51 year old woman, whose brain autopsy showed plaques and tangles that characterize AD [8].

AD is a degenerative brain disease of unknown origin, usually developing slowly during the late middle age or in old age and worsens with time. AD results in progressive memory loss, impaired thinking, disorientation, changes in personality and mood. These symptoms are leading to profound decline in
cognitive and physical functioning, which is histopathologically characterized by degeneration of brain neurons, especially in the central cortex, and by the presence of neurofibrillary tangles and plaques containing β amyloid [7, 9, 10] (Table 1).

Risk factors and protective circumstances

Given the presence of numerous interconnected genetic and environmental factors, AD is unquestionably considered as a complex multifactorial disease. However, its cause or causes are not known. Risk factors are grouped into two categories: Those that cannot be altered and others that are possible to modify [11].

Non modifiable risk factors

Age: AD is not part of the normal ageing process, but age is the strongest independent risk factor for the development of AD. This does not mean that most people develop AD as they age, and in fact most do not. However, some younger people still in their 40s and 50s can be diagnosed with the early onset form of the disease. Over the age of 65 years the risk of developing AD doubles ca. every five years. In the US for example the incidence of AD within the age group of 65-74 years is 2 per 1,000 people, in the age group of 75-84 years it is 13 and in the >85 years group 39 per 1,000 people. According to the Framingham study, the estimated lifetime risk for AD is 9.1% for men and 17.2% for women at age of 65 years; 10.2% and 18.5% at 75 years; 12.1% and 20.3% at 85 years, respectively [7].

Gender: Age related loss of sex steroid hormones is an established risk factor for the development of AD in both men and women. Estrogens and androgens exert general neuroprotective properties, including protection from neuronal death, increase spine density, facilitate synaptic plasticity and improve certain aspects of cognition. In addition, estrogens and androgens regulate key processes implicated in AD pathogenesis. Due to the loss of estrogen and progesterone, β amyloid protein (Aβ) accumulation and tau phosphorylation are increasing.

Evidence suggests that AD pathogenesis is regulated by estrogen and progesterone in females, but primarily by androgens in males [12, 13].

Menopause: It is known that AD is more prevalent in women, than in men. The higher prevalence of AD in women can be partly explained by the differences in life expectancy, however according to several studies, the incidence of AD is also higher in women. Moreover, AD pathology and AD-related cognitive decline are more marked in women than in men. This can be partly justified by the relatively abrupt loss of oestrogen and progesterone in women and the more gradual decrease of testosterone level in men. The 17beta-estradiol concentration in the female brain decreases sharply at menopause, but with very little additional decrease with ageing afterwards. Moreover, there is a stronger association with apolipoprotein Eε4 Allele (APOEε4) in AD in women than in men, and this association correlates with greater hippocampal atrophy in women. The underlying cause for increased vulnerability of females to AD-like pathology is ambiguous.

Hormone Replacement Therapy (HRT) in menopausal women seems to offer promising results in reducing the risk of AD. Controversially, according to a prospective study, HRT may even increase the risk of dementia. Recent clinical data suggest that AD risk is reduced when HRT is initiated in midlife, but is exacerbated by HRT administration in late life [12, 13].
Alzheimer’s Disease: An Epidemiologic Disaster From Nutritional Perspective

<table>
<thead>
<tr>
<th>Table 1: Stages of Alzheimer's disease [10]</th>
<th>Moderate Alzheimer's disease (middle-stage) lasts for 2-10 years</th>
<th>Severe Alzheimer's disease (late stage) lasts for 1-3+ years</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mild Alzheimer's disease (early-stage) lasts for 2-4 years</strong> in the early stages of AD the patient may function independently</td>
<td>As the disease progresses, the patient will require a greater level of care</td>
<td>As memory and cognitive skills continue to worsen, personality changes may occur and patients need extensive help with daily activities</td>
</tr>
<tr>
<td>- Difficulty by performing tasks in social or work settings - Forgetting text that one has just read - Losing or misplacing objects - Increasing problems with planning or organizing</td>
<td>- Forgetting events or own personal history - Feeling unpredictable or withdrawn in socially or mentally challenging situations - Unable to recall own address or phone number - Confusion about present time and location - Need for help choosing proper clothing for the season or occasion</td>
<td>- Full-time assistance needed with daily personal care - Lose awareness of recent experiences and surroundings - High levels of assistance required with daily activities and personal care - Experience changes in physical abilities (incl. the ability to walk, sit, swallow) - Increasing difficulty communicating - Vulnerable to infections, esp. pneumonia</td>
</tr>
<tr>
<td><strong>Middle Alzheimer's disease</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Genetics:** AD can be categorized into two subtypes: Early onset AD (EOAD) or familial AD (FAD) and late onset AD (LOAD) [14].

I. Familial AD

FAD is expressed as a Mendelian trait with dominant inheritance, and around 2-5% of all AD cases belong to this category. If a person has FAD, each of their children have 50% chance of inheriting the disease; when both parents have FAD, their children will develop AD in adulthood. FAD cases occur in people between the age of 30-60 years. Characteristic pathological features in the brain include progressive accumulation of \( \text{A}\beta \) in the form of senile plaques outside the neurons, and twisted strands of protein (neurofibrillary tangles, hyperphosphorylated tau protein) inside the neurons. These changes are eventually accompanied by low-grade chronic inflammation and oxidative stress, causing neuron damage and cerebral cortical atrophy, which in the long run leads to dementia [14, 15].

a. Amyloid Cascade Hypothesis (ACH): According to the ACH, the deposition of \( \text{A}\beta \) is the initial event in AD, leading to the formation of extracellular senile plaques and then to neurofibrillary tangles, neural cell death and ultimately clinical dementia [16].

Specially three mutations in the genes of the Amyloid Precursor Protein (APP), Presenilin1 (PSEN1) and Presenilin2 (PSEN2) result in the alteration of \( \text{A}\beta \), and cells produce \( \text{A}\beta \) peptides of variable length: A peptide of 40 amino acids (\( \text{A}\beta_{40} \)) is the most prevalent, whereas the longer \( \text{A}\beta_{42} \) isomer appears to be the key pathogenic form for FAD. During physiological circumstances, APP is cleared by \( \alpha \)-secretase, producing a dissolved form (amyloid \( \alpha \)) which is released into the extracellular compartment [17, 18].

Neuronal microtubules transports nutrients, molecules and information to other cells. Tau protein plays a key role in keeping the microtubule system stable. In AD the threads of tau become disintegrated, collapsing the entire neuronal transport system. Plaques and highly Phosphorylated Neurofibrillary Tangles (NFT) lead to functional failure of synapses, synaptic loss and finally neural death [19].

However, the current hypothesis of amyloid cascade and tau pathology only partially explains the pathophysiology of AD, which is considered to have a multifactorial etiology. Musiek and Holtman argued that \( \text{A}\beta \) acts primarily as a trigger of other downstream processes, particularly tau aggregation, which mediate neurodegeneration: Thus \( \text{A}\beta \) appears to be necessary, but not sufficient to cause AD by itself. At the same time Herrup also rejects the ACH and suggests that amyloid is not even necessary for AD development. Most probably a “multiple reason” hypothesis will be able to account for all the various aspects that underline the disease process, and to differentiate between normal and pathological brain ageing [20, 21].

A comprehensive review by Morris et al. summarized the pros and cons of the amyloid cascade hypothesis. They concluded that \( \text{A}\beta \) in the AD brain is a consequence rather than the primary
cause of the disease. Since the amyloid hypothesis is still incomplete and also highly debated, it is worthwhile to consider other alternative theories [22].

b. Aβ Clearance Systems: It has been hypothesized that Aβ accumulation results from an imbalance between Aβ production and clearance. Aβ clearance seems to be impaired in both early and late forms of AD. Recently, the clearance systems of the brain were described in relation with AD pathology, and with a special focus on Aβ: the blood-brain barrier clearance, the intra- and extracellular degradation clearance, the interstitial fluid bulk flow clearance and the cerebrospinal fluid adsorption clearance. The precise understanding of the mechanisms of clearance dysfunction in AD is essential for developing strategies to reduce excess deposition of neurotoxic proteins and to stop the related pathological changes. It still remains a question whether the observed clearance defect in AD is a cause or a consequence of the pathology or merely a coincidence. Further examination of the Aβ clearance defect might provide a useful biomarker for the reversible clinical pathology of AD [23].

II. Late Onset AD (LOAD)

LOAD usually develops in patients older than 60 years of age. The causes are not completely understood yet, but genetic, environmental and lifestyle factors may contribute to the progression and severity of this form of the disease. Nevertheless, based on clinical evaluation of a community population sample, the prevalence is strongly associated with age: 3% between 65-74 years; 18.7% between 75-84 years; and 47.2% over 85 years [24].

Apolipoprotein E (APOE) is a major determinant of the fat soluble vitamin transport in blood to the peripheral tissues, as well as in the central nervous system to neurons via APOE receptors. APOE is polymorphic with three major alleles: ε2, ε3, and ε4. The APOE ε2 form is carried by 9%, ε3 about 77% and ε4 around 15% of the population, respectively. It has been proposed that APOE ε2 may provide some protection against AD, while APOE ε3, the most frequent allele is believed to play a neutral role in the disease, although both APOE ε2 and ε3 may enhance the clearance of Aβ. There are data showing that APOEε2 reduces the risk of dementia in persons older than 90 years. APOEε4 probably increases the risk of AD by initiating and accelerating Aβ accumulation in the brain. This allele is present in 40% of patients with LOAD, and it is considered to be the major genetic risk factor of AD. However, inheriting an APOE ε4 allele does not necessarily mean a definitive development of AD, but the risk of LOAD is ca. 8-10 times higher in homozygous individuals as compared to the risk in heterozygous persons [18, 25-27]. Furthermore it has been demonstrated that APOEε4 accelerates age dependant cognitive decline and worsens memory performance and functional activities as well as hippocampal atrophy [26, 28].

Epidemiological, in vitro and animal studies suggested that APOEε4 causes neuronal disturbances and behavioural deficits in vivo via multiple ways, either in dependently or in combination with other factors, such as Aβ and tau. APOEε4 contributes to the impairment of the oxidative defence system, dysregulation of neuronal signalling pathways, increased phosphorylation of tau and formation of neurofibrillary tangles. [26, 27, 29].

Modifiable risk factors, life-course concept

This theory aims to understand how risk factors and protective circumstances interact during gestation, childhood, adolescence, and adult life to influence the development of later disease [30].

Intrauterine life is important for the maturation and development of the brain and the nervous system. In turn, brain development may influence the risk of cognitive impairment and dementia in older age.

The brain reaches 95% of its final size at age 6, the maximal brain size and skull circumference are reached between 11 and 15 years. Thereafter brain size decreases, while skull circumference remains constant. Thus the circumference of the adult skull reflects the brain size at its peak [30]. The individual capacity to withstand pathological alterations is usually referred to as Brain Reserve (BR) or Cognitive Reserve (CR) [31].

BR refers to qualitative measures, such as brain size, number of neurons and synapses. BR is a passive protection against the consequences of brain damage, mediated by larger brain or more neurons and synaptic connections [31]. Epidemiological and clinical studies have consistently shown that at similar levels of AD pathology, higher estimates of BR and greater Intracranial Volume (ICV) were related to less severe symptoms. Perneeczky et al. involved in the Mirage study suggested that larger head circumference is associated with less cognitive impairment. The larger brains contain more neurons, synaptic connections and bigger brain size is mostly determined in early childhood. The results suggest that optimal neural development in the first couple of years provides a buffer against cerebral pathology in late life [31]. Although greater premorbid brain size seems to protect against clinical deterioration in AD related brain atrophy in Mild Cognitive Impairment (MCI), the protective effects of morphologic reserve seem to be limited to early clinical AD [32].

CR is characterized by active processes through alternative neural pathways, helping to compensate the effect of brain pathology in its clinical presentation. CR includes compensatory strategies like education, Intelligence Quotient (IQ), literacy and the integrity of social networks. Epidemiological data suggest that persons with higher education, occupational competence and participation in leisure activities have a lower risk for developing AD [33]. It is widely accepted that CR is an important protective factor against AD, but the question remains how to maximize CR of individuals. In this regard several suggestions have been proposed by Stern, such as the extension of the person’s social network, early life education and cognitive activities in later life [34].

Nutrition

There is an increasing interest to clarify the role of nutrition in AD. This review is focusing on certain key nutritional compounds and a few diseases/disorders that may be connected to AD. It also takes these factors into account concerning the development and
progression of AD, and their role in prevention. As AD is currently incurable, these factors need to be very carefully investigated.

1. **Vitamin E:** Significant positive association was found for the beneficial effect of vitamin E and the prevention of AD: Grade I evidence indicates that vitamin E may decrease the risk for the development of AD [35].

Vitamin E is a fat soluble vitamin with eight isoforms: α-, β-, γ-, δ-tocopherol and α-, β-, γ-, δ-tocotrienol. All forms have a chromanol ring with a hydroxyl group that can serve hydrogen atom to reduce free radicals, and a hydrophobic side chain which allows its penetration into biological membranes. The human body preferentially uses α-tocopherol; this form is found in the cells [36].

It has been suggested that vitamin E may prevent hyperphosphorylated tau protein dysfunction. Additionally, vitamin E has been related to reduced rate of neuronal death induced by Aβ protein in cultures of hippocampal and cortical cells [37].

**a. Function of α-tocopherol:**

1.) **Antioxidant activity:** Alpha-tocopherol is a chain breaking antioxidant preventing the propagation of Reactive Oxygen Species (ROS) in membranes and in plasma lipoprotein. When a molecule of α-tocopherol neutralizes ROS, it oxidizes to a less active tocopherol radical, which is reduced by a hydrogen donor such as vitamin C. In this way the chain reaction of lipid peroxidation is broken [36].

**b. Clinical trials concerning vitamin E supplementation:** Compared to cognitively normal subjects, AD and MCI patients have lower blood concentrations of total tocopherols, total tocotrienol and total vitamin E [41].

According to the Cochrane database, only three studies met the inclusion criteria to investigate the effect of vitamin E in the treatment of MCI or AD [42].

Sano et al. investigated the effect of selective monoamine oxidase inhibitor selegiline (10 mg/d), α-tocopherol (2,000 IU/d) or both and placebo for two years. In patients with moderately severe impairment form of AD, treatment with selegiline, α-tocopherol or their combination slowed the progression of the disease [43].

Lloret et al. treated patients with 800 IU vitamin E/d or placebo for six months. Blood oxidized glutathione (GSSG) was measured and cognitive tests were analyzed. Patients were divided in two groups: In the “respondents” to vitamin E, GSSG levels were lower after treatment and scores of cognitive tests were unchanged. In the “non-respondent” group, vitamin E was not effective in preventing oxidative stress, and cognition decreased sharply. Authors suggested that vitamin E supplementation in AD patients cannot be recommended without the determination of its antioxidant effect in each patient [44].

Petersen et al. administered 2,000 IU vitamin E daily, 10 mg of donepezil daily or placebo to patients with amnestic subtype of MCI for three years. They concluded that vitamin E had no benefit for patients with MCI [45].

According to the conclusion of the Cochrane group, there is no convincing evidence that vitamin E is beneficial for the treatment of AD and MCI, and future trials assessing vitamin E treatment in AD should not be restricted to α-tocopherol [42].

One of the largest and longest treatment trials, involving patients with mild to moderate AD, studied the effect of α-tocopherol (2,000 IU/day) or memantine (20 mg/d) alone or in combination, versus the combination of placebo and Acetylcholinesterase (ACE) inhibitor medication over a period of six months to four years. The results showed that a dosage of 2,000 IU/d α-tocopherol significantly delayed the progression of AD symptoms in mild to moderate AD and decreased caregiver burden. Moreover, the authors found no safety concern associated with vitamin E supplementation compared to the control group [46].

There are several ideas to explain the inconsistent results on the effect of vitamin E supplementation. According to Brewer’s hypothesis, the antioxidant vitamin E is ineffective because the oxidized vitamin E is not removed from the membranes and is not reduced by vitamin C or any other antioxidant. Therefore it will either accumulate or pass the electron to another lipid, further damaging the membrane [47]. However, there is another possibility. Generally, α-tocopherol is used as a supplement in clinical trials, but γ-tocopherol was found more effective in scavenging free radicals and nitrogen oxygen species that cause inflammation. Moreover, α-tocopherol supplements significantly increase the concentration of α-tocopherol in plasma, but not in brain [48].
reduces serum γ-tocopherol concentration and this may have important biological effects. Therefore, α-tocopherol may eliminate the favourable effects of other forms of vitamin E in MCI and AD [48, 49].

Recently it was discussed in a comprehensive review that the difficulty in performing precise and uniform human studies is mostly responsible for the inconsistent outcomes reported in the literature. Therefore more standardized clinical research is needed to identify a clear effect of vitamin E on cognitive decline observed during aging and AD progression from early to late phase [50].

Nutrition epidemiologic studies indicate that vitamin E from food sources may be more effective at preventing age related neurodegenerative disorders than dietary supplements. This could be partly explained by the fact that vitamin E from foods comprises all four tocopherols and four tocotrienols with different properties. Besides this, the combination of nutrients from food may have synergic effects [48, 49].

II. Vitamin C: The beneficial effect of high vitamin C intake on AD and MCI has grade I evidence [35].

Vitamin C (ascorbic acid, the y-lactone of hexonic acid) is a water soluble vitamin. It is a very unstable compound and readily undergoes oxidation to dehydroascorbic acid. Vitamin C has a huge redox potential. It is a potent antioxidant and essential cofactor in numerous enzymatic reactions, e.g. in the biosynthesis of collagen, carnitine and catecholamine and is involved in the metabolism of cholesterol. It also increases the intestinal absorption of non-hem iron.

Sodium dependent adsorption of vitamin C is limited, 100% adsorption is observed at dose of 200 mg. When plasma vitamin C level reaches saturation, additional vitamin C is largely excreted into urine [51].

The effect of vitamin C was investigated on Aβ formation and behaviour in an AD mice model. Due to the effect of vitamin C, the reduction of Aβ oligomerization was accompanied by marked decrease in brain oxidative damage and in the ratio of soluble Aβ42 to Aβ40, a typical indicator of AD progression. Moreover, vitamin C attenuated the phosphorylation of tau, but brain plaque deposition was not altered [52].

It has been shown, that as compared to control subjects, plasma vitamin C concentration is lower in AD patients and is negatively associated with the degree of cognitive impairment. This correlation seems to be independent of age, gender, Body Mass Index (BMI), diet, and vitamin C intake. AD subjects have increased lipid peroxidation levels and free radicals may cause damage in the neural tissue [53, 54].

However, the literature implicating vitamin C and other antioxidants in the promotion of cognitive function and the prevention of AD are conflicting. The relationship between AD and intake of vitamin C and/or E was investigated in elderly, who were free of dementia at baseline, and were followed on prevention of AD are conflicting. The relationship between AD and intake of vitamin C and/or E was investigated in elderly, who were free of dementia at baseline, and were followed on prevention of AD progression from early to late phase [50].

Recent studies have measured vitamin C in the Cerebrospinal Fluid (CSF). Higher CSF to plasma vitamin C ratio at baseline was associated with a slower rate of cognitive decline at a one year follow up study. The strength of this relationship was modified by CSF albumin index, a marker of Blood-Brain-Barrier (BBB) integrity. The CSF albumin index attenuated the association of CSF-plasma ascorbic acid ratio with cognitive outcomes. It has been suggested that BBB dysfunction may lead to diffusion of vitamin C from the Central Nervous System (CNS) and may impair the brain’s ability to maintain the high CSF-plasma ratio in AD [60].

Epidemiological studies confirmed the relevance of the relationship between vascular disease and AD. Polidori et al. investigated the connection between the level of several antioxidants and Carotid Intima-Media-Thickness (C-IMT), as an indirect index of vascular damage. They established that higher vitamin C plasma levels appears to be protective against elevated C-IMT values in elderly. In the light of increased risk of cardiovascular disease, cerebrovascular disease and cognitive impairment shown in patients with increased C-IMT, the achievement of better antioxidant status in general and vitamin C in particular should be always encouraged in the elderly [61].

III. Folate: Folate is a generic term, referring to both natural folates (pteroyl glutamate) in the food and folic acid (pteroyl-l-glutamic acid), the synthetic form used in supplements and fortified food. Folate is a coenzyme and its principal role is to accept or donate one-carbon units. Vitamin B2 (riboflavin), vitamin B6 (pyridoxine) and vitamin B12 (cyanocobalamin) are required for the folate metabolism to serve one-carbon units [62, 63].
One of the key enzymes in the folate metabolism is 5,10-Methylene Tetrahydro Folate Reductase (MTHFR) that catalyzes the reduction of 5,10-methylene tetrahydrofolate to 5-methyltetrahydrofolate, the methyl donor for methionine synthesis from homocysteine [62].

MTHFR is a rate-limiting enzyme in the methyl cycle, and it is encoded by the MTHFR gene. The MTHFR nucleotide at position 677 in the gene has two variants: C (cytosine) or T (thymine). C at position 677 is the normal allele, the 677 T allele encodes a thermolabile enzyme with reduced activity. Homozygous individuals with two copies of 677C (677/C/C) have the most frequent genotype, while people with the 677T/T variant have lower MTHFR activity than C/T or C/C individuals. Thus homozygous 677T/T persons have higher Homocysteine (Hct) concentrations, and Hct shows negative (grade L) association with AD as shown below [35].

Depending on the population, 20-53% of individuals may have inherited one T copy (677C/T genotype) and 3-32% of the individuals may have inherited two T copies (677T/T) for the MTHFR gene, compared to individuals with the most frequent 677 C/C homozygous genotype [64, 65].

There are numerous studies investigating the association between MTHFR genotypes, folate, vitamin B6, B12 intake and serum levels and Hct concentrations in connection with AD. Religa et al. found that the concentration of plasma total Hct is increased in AD patients and this may be associated with T/T genotype in the MTHFR gene [66]. Recently, a comprehensive meta-analysis was performed involving in total 68 studies. Hct, folate acid and vitamin B12 levels in AD patients in comparison with controls, and their association with the risk of AD were evaluated. According to the results, AD patients may have lower levels of folate and vitamin B12 and higher level of Hct in plasma than controls. An age-subgroup analysis showed no age effect for Hct levels in plasma between AD patients and matched controls, while the differences in folate and vitamin B12 levels further expanded with increasing age. Data also suggested that high Hct and low folate levels may correlate with increased risk of AD occurrence [67].

Another comprehensive review and meta-analysis examined the role of vitamin B supplementation on MCI and AD. Results showed moderate beneficial effects of vitamin B supplementation on memory, whereas no significant difference on general cognitive function, executive function and attention were found in MCI patients. No significant cognitive benefits on the AD Assessment Scale and Mini Mental State Examination, functional, behavioural or global change were observed in AD patients. Collectively weak evidence of benefits were observed for the domains of memory in patients with MCI. Recent data does not yet provide adequate evidence of an effect of vitamin B on general cognitive function, executive function and attention in people with MCI. Similarly, folic acid alone or vitamin B in combination were unable to stabilize or slow down decline in cognition, function, behaviour and global change of AD patients [68].

A third meta-analysis investigated the effects of Hct lowering effect of B vitamin treatment on cognitive function and on the rate of cognitive age. According to the results, B vitamins lowered Hct concentrations, but had no significant effect on individual cognitive domains or global cognitive function or cognitive ageing [69].

IV. Vitamin D: Vitamin D is a fat-soluble secosteroid hormone. It exists in two isomorphs: Vitamin D3 (cholecalciferol) is synthesized in the skin, and vitamin D2 (ergocalciferol) is photosynthesized in plants. These inactive precursors are metabolized in the liver and kidneys. Following synthesis in the epidermis or dietary intake, both forms enter the circulation and are transported to the liver by the vitamin D binding protein. In the hepatocytes the inactive form is converted to 25-Hydroxyvitamin D3 or D2 (25(OH)D) which is activated in the kidney. The metabolically active form, 1,25-Dihydroxyvitamin D (1,25(OH2)D) is binding to Vitamin D Receptor (VDR) and directly or indirectly regulate hundreds of genes.

The major circulating form of vitamin D is the sum of 25(OH)D3 and 25(OH)D2 and used as a biomarker of vitamin D nutritional status [70]. VDRs are present in all the brain regions that are essential for cognition. Annweiler summarised the potential roles of vitamin D mediated by VDRs in the central nervous system as follows: Clearance of Aβ peptide; regulation of the intraneuronal calcium; anti-inflammatory action; anti-oxidative action; primary prevention and reduction of ischemic zone size; regulation of cholinacetyltransferase; regulation of neuro trophic agents [71].

a. Observational studies: Epidemiologic studies indicated that people with AD have lower vitamin D status than controls. A meta-analysis on the 25(OH)D status involving six studies proved that AD patients had lower levels of 25(OH)D than aged matched controls [71, 72]. Cross sectional and case control studies confirmed also that vitamin D concentrations are lower in individuals with cognitive impairment and dementia [73]. Recently published meta-analyses indicated that lower vitamin D status may be associated with an increased risk of developing dementia and AD [74].

b. Supplementation studies: Annweiler et al. studied the effect of vitamin D or memantine alone or combined in 43 outpatients (mean age 84.7 ± 6.3 years; 65.1%women) with new diagnosis of AD. Patients who took memantine plus vitamin D for six months had statistically and clinically increased cognitive improvement, meanwhile vitamin D or memantine alone showed no effect [75]. These results suggest that vitamin D supplementation is not sufficient to prevent AD by itself and so the development of a multi-target drug is necessary, using vitamin D supplements as an adjunct to standard anti-dementia treatments [71]. Based on the available data, the Vitamin D Council also concluded that other treatment should not be replaced by vitamin D in AD patients [76].

New theories for the development of AD

Vitamin D hypothesis: In early 2014, Gezen-Aket et al. presumed that long-term-hypovitaminosis D or inefficient
The role of arginine: Kan et al. studied the immune system of the CVN-AD mouse, a model of human AD. In the brain of the mouse model plaques, tangles and hippocampal neuron death are present, resulting in rodent memory loss. Areas of hippocampal neuron death were associated with the immunosuppressive CD11c+ microglia and extracellular arginase, resulting in arginine catabolism and reduced level of total brain arginine. Difluoromethyl-Ornithine (DFMO) was used to block arginase before the symptoms of AD appeared. As a result, fewer plaques could be identified and the mice performed better on memory tests. This study suggests that in AD certain immune cells that normally protect brain begin to abnormally consume arginine. The data indicate that immune suppression and arginine catabolism lead to a loss of arginine and its deprivation is followed by cell death. Authors concluded, that in contrast to previous views which considered AD as driven by immunity and inflammation, it is rather associated with an immunosuppressive pattern [78].

The study of Kan et al. has been commented by several experts [79]: Spiers-Jones highlighted that the results need to be confirmed in other models as well before moving into human studies. According to Picket, the next step would be to show that targeting arginine metabolism in the brain can reduce the death of brain cells. Phipps warned that clinical trials are essential before any potential new treatment can be given to people. The question raised, whether arginine supplementation can prevent AD. Arginine supplementation is not recommended, because the blood-brain barrier would prevent arginine to go into the brain, and even if it does get through, arginine would be still degraded by the arginase enzyme [80].

The best way to maintain a healthy brain throughout the life is to ensure a balanced diet, no smoking, being mentally and physically active with regular exercise, and to keep blood pressure and cholesterol level controlled, as summarised by Phipps.

It is undeniable that the hypothesis of Kan generated a new idea in Alzheimer research, but it needs more data to prove it [79].
to cognitive function improvement. Generally, fish intake maybe associated with a healthier dietary pattern, and high fish intake maybe associated with lower intake of other types of fat, such as saturated fat. This meta-analysis also showed that the higher intake of fish was associated with lower risk of AD, while ω-3 PUFAs intake did not influence the risk of dementia and AD [88].

The role of diabetes: Some papers suggest a connection between Type 2 Diabetes Mellitus (T2DM) and dementia and AD [89-91]. However, the findings are inconsistent. Some studies state that there is no direct relationship between AD and diabetes. It seems that diabetes is more strongly and consistently associated with vascular form of cognitive impairment rather than with AD like neurodegenerative forms [92, 93].

A recently issued meta-analysis showed no evidence based association between T2DM and AD in western population, however there is a significant association between T2DM and AD in Asian population [35].

To absolve this inconsistency, a concept has been proposed that AD might represent a specific form of brain diabetes and so de La Monte and Wands put forward the term ‘type 3 diabetes’ that selectively involves the brain. They proved with human and experimental animal studies that CNS impairments in Insulin/Insulin Like Growth Factor (IGF) signalling mechanism can occur in the absence of Type 1 And 2 Diabetes Mellitus (T1DM and T2DM). T2DM was not sufficient to cause AD, although it could be possible serve as a cofactor in its pathogenesis or progression. They concluded that AD is a neuro endocrine disease caused by selective impairments in insulin and IGF signalling mechanism, including deficiencies in local insulin and IGF production. The accompanying inflammatory response, oxidative stress, DNA damage and mitochondrial dysfunction have also been proposed to contribute to the degenerative cascade causing brain damage [94].

Obesity: A recent meta-analysis estimated grade I. evidence for high BMI in midlife as well as low BMI to be correlated with AD [35]. However, the available evidence from epidemiological studies associated with overweight and obesity as measured by BMI in midlife is still conflicting. The relationship between BMI in midlife and late-life and dementia was investigated in another meta-analysis. According to the follow-up prospective study in midlife, Underweight, overweight and obese BMIs were associated with increased risk of dementia as compared to the normal BMI. Risks appeared to be the highest for underweight and obese BMI. An U-shaped relationship was suggested between midlife BMI and late-life risk of dementia. Findings were similar for AD as well. But in late-life continuous BMI was not associated with dementia, probably because of some methodological factors, such as the insufficient length of follow-up and the small size of the groups [95].

According to a prospective population-based cohort with a 26 years follow-up study, higher midlife (mean age: 50.2 ± 6.0 y) BMI was related to higher risk of dementia and AD. Steeper decrease of BMI and low late-life (mean age: 71.2 ± 4.9 y) BMI were associated with higher risk of dementia and AD [96].

Luchsinger et al. compared the predictive value of BMI to dementia. Hazard ratios relating quartiles of BMI to dementia in persons <76 years old and persons ≥76 years old were characterized. In persons <76 years old the association between BMI and dementia resembled an U-shape, the second and third quartiles were related to lower risk, while the fourth was similar to the reference. In older people, the risk of dementia decreased with increasing BMI. Continuing this study authors explored whether measures of central obesity were better predictors of AD compared to BMI in elderly. They established that the association between adiposity and dementia differs depending on an anthropometric measures used and is modified by age. It has been shown that BMI loses predictive ability in the elderly and Waist Hip Ratio (WHR) is a better predictor of AD compared to other measures. It also helps to explain the apparent discrepancies in studies reporting on obesity in elderly and AD [97, 98].

The effects of some modifiable risk factors for AD and dementia are highlighted in Table 2.

Dietary patterns and guidelines

Diet and nutrition might be important modifiable risk factors of AD. Single nutrients are not consumed in isolation but as part of a diet. Examining the role of a single nutrient is difficult also due to the interaction between the different nutrients. Therefore examining foods, rather than single nutrients might be more useful [41]. Recently dietary pattern analysis was introduced, as a way for examining diet-disease relations in AD. Dietary pattern is defined as quantities, proportions, variety or combination of different foods, drinks and nutrients in diets and frequency, with which they are habitually consumed [99]. Among dietary patterns, Mediterranean, Japanese and healthy diets have been reported to be associated with lower risk of AD. However, further studies are needed to explore the importance of diets in dementia and AD [41].

A subgroup of the Dietary Guidelines Advisory Committee (DGAC52) assessed the connection between several dietary patterns, food and nutrients and dementia and AD. They concluded that patterns higher in fruits, vegetables, nuts, legumes and seafood were generally associated with reduced risk; patterns higher in red and/or processed meats were generally associated with greater risk; relatively few studies reported on refined sugar and added salt, but patterns including these nutrients tended to report greater risk [99].

At the International Conference on Nutrition and Brain, experts recommended guidelines for AD prevention as follows [100]:

1.) Minimize saturated trans-fat intake

2.) Vegetables, fruits, legumes and whole grains should replace meat and dairy products

3.) Vitamins should come from food, however, recommended intake and adequate status is difficult to achieve

4.) A reliable source of vitamin B12 providing at least the recommended daily allowance

### Table 2: Effect of some modifiable risk factors for AD and dementia

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study selection</th>
<th>Purpose</th>
<th>Number of studies included, sample size</th>
<th>Main outcome</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Farina et al. 2012 [42]</td>
<td>Double-blind randomized trials</td>
<td>To assess the efficacy of Vitamin E in the treatment of AD and prevention of progression of MCI to dementia</td>
<td>Two studies analyzed in AD and one in MCI population</td>
<td>First of the AD studies: reported some benefit from Vitamin E (Sano); Second AD treatment study: patients whose oxidative stress markers were lowered by Vitamin E showed no improvement in cognitive status (Lloyd); Third study: Vitamin E had no beneficial effect on progression from MCI to AD.</td>
<td>No convincing evidence that Vitamin E treatment is beneficial in the treatment of AD or MCI. In some cases increased mortality. Vitamin E should not be used for the treatment of MCI and AD. More trials are needed and these should include different forms of Vitamin E.</td>
</tr>
<tr>
<td>ADDF 2014 [59], Li et al. 2012 [103]</td>
<td>n/a</td>
<td>Evaluate the association between dietary intake of Vitamin C, E, β Carotene and risk of AD</td>
<td>n/a</td>
<td>Dietary intake of these antioxidants can lower the risk of AD. Vitamin E exhibiting the most pronounced protective effects.</td>
<td>Analyses 1) confirmed higher Hcy, lower folate and vitamin B12 levels are in AD patients; 2) Data suggests that high Hcy and low folate levels may be risk factors of AD.</td>
</tr>
<tr>
<td>Shen &amp; Ji 2015 [67]</td>
<td>Comprehensive meta-analysis</td>
<td>To evaluate: 1) Hcy, folic acid and Vitamin B12 levels in AD patients; 2) the association between Hcy, folic acid and B12 levels and risk of AD</td>
<td>68</td>
<td>1) AD patients may have higher level of Hcy and lower levels of folate and Vitamin B12. 2) No age effect for Hcy level in plasma.</td>
<td>Data does not provide adequate evidence of an effect of Vitamins B on general cognitive and executive functions and attention in people with MCI. Folic acid alone or Vitamins B alone or in combination are unable to stabilize or slow decline in cognition, function, behaviour and global change in AD.</td>
</tr>
<tr>
<td>Li et al. 2014 [68]</td>
<td>n/a</td>
<td>To assess the efficacy of Vitamins B supplementation in slowing the rate of cognitive, behavioral, functional and global decline in MCI and AD patients</td>
<td>5 trials were analyzed</td>
<td>1) Moderate beneficial effects of Vitamins B supplementation in memory, no significant difference in cognitive and executive functions, and attention in MCI 2) No significant benefits on cognitive functions in AD.</td>
<td></td>
</tr>
<tr>
<td>Clarke et al. 2014 [69]</td>
<td>Placebo-controlled randomized trials</td>
<td>To assess the effects of treatment with Vitamins B administered for several years, compared to placebo on composite domains of cognitive functions, global cognitive functions and cognitive aging</td>
<td>11 large randomized trials in 22,000 patients. Domain-based Z scores (memory, speed and executive function) before and after treatment (mean ~2.3y) in the 4 cognitive domain trials (n=1,340) MMSE-Type tests at the end of treatment (mean ~5y) in 7 global cognition trials (n=20,431)</td>
<td>Domain-composite and MMSE-type global cognitive function Z scores decreased with age. B vitamins lowered Hct in cognitive-domain trials, but no significant effects on the Z scores differences from baseline for individual domains or for global cognitive function - similar effect in the global cognition trials.</td>
<td>Hcy lowering with B vitamins has no effect on individual cognitive domains or global cognitive functions nor cognitive aging.</td>
</tr>
<tr>
<td>Zhao et al. 2013 [72]</td>
<td>n/a</td>
<td>To examine the 25(OH)D status in AD patients</td>
<td>6 studies, 319 patients and 573 controls</td>
<td>AD patients had lower levels of 25(OH)D levels than controls</td>
<td>Despite the similar mean age of AD patients and controls, patients had lower levels of 25(OH)D than controls.</td>
</tr>
</tbody>
</table>
5.) If using multivitamins, choose those without iron, copper.
6.) Although aluminium’s role in AD remains a matter of investigations those who desire to minimize their exposure can avoid to use products that contain aluminium.
7.) Include aerobe exercise in your routine.

**Conclusion**

Considering that the incidence and prevalence of currently incurable AD is constantly and rapidly increasing in the ageing societies worldwide, besides pharmaceutical drug development there is an urgent need for alternative solutions for both prevention and treatment. Optimizing the nutritional status of the general population as a preventive measure may provide additional support to therapeutic concepts as they become available [5]. However, currently the scientific evidence regarding the effects of diet and nutrients on AD is incomplete and there are still a lot of opportunities for the nutrition scientists to contribute to the clarification of the conflicting results and adjust guidelines accordingly [100, 101]. Nevertheless, pathophysiological characteristics of AD such as neuroinflammation, glucose dysregulation, homocysteine accumulation and neuronal loss can be considerably and positively influenced by proper nutrition [102]. Moreover, already several RCTs have demonstrated promising results for nutrients to decrease the risk of developing AD and maintaining cognitive performance. Thus, lifelong optimal supply of essential micro- and macronutrients may greatly contribute to delay the onset of AD.

**Conflict of Interest**

MA received an honorarium from DSM Nutritional Products Ltd. for writing the article. SP and ME are employees of DSM Nutritional Products Ltd.

**References**

8. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English
Alzheimer’s Disease: An Epidemiologic Disaster From Nutritional Perspective


70. Higdon J. Vitamin D. Linus Pauling Institute Micronutrient Information Center; 2014 [cited 2016 July 13]; Available from: http://lpi.oregonstate.edu/mic/vitamins/vitamin-D.


Alzheimer’s Disease: An Epidemiologic Disaster From Nutritional Perspective